Blood Advances · 2019 · 19 citations · 16 references
Hematological MalignancyMolecular PharmacologyC-myc ExpressionMedicinePharmacologyKey Points TeriflunomideMyelopoiesisCancer BiologyPharmacotherapyAnti-cancer AgentCell BiologyVivo Mm ModelOncologyRadiation OncologyCancer ResearchTumor BiologyDrug Discovery
Key Points Teriflunomide, the active metabolite of leflunomide, downregulates c-Myc expression through inhibition of PIM kinases. Leflunomide together with lenalidomide significantly extended survival in an in vivo MM model.
16